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PEMBANGUNAN KIT EZDNA DIAGNOSTIK UNTUK PENGESANAN
KEHILANGAN HOMOZIGUS GEN SMN1 PADA PESAKIT ATROPI OTOT
SPINA (SMA)
ABSTRAK
Spinal Muscular Atrophy (SMA) adalah penyakit yang mempunyai frekuensi yang
kedua tertinggi yang menyebabkan kematian dikalangan kanak-kanak. Kadar kejadian
penyakit ini adalah didalam anggaran 1 setiap 10000 kelahiran. SMA digambarkan
melalui kelemahan otot secara beransur-ansur akibat daripada kemerosotan dan
kehilangan neuron motor didalam bahagian hadapan tulang belakang. Survival of Motor
Neuron (SMN) merupakan gen yang bertanggungjawab terhadap penyakit SMA. Gen
SMN1 dan SMN2 berkongsi lebih dari 99.8% jujukan yang sama dan ia hanya boleh
dibezakan dengan perubahan bes pada exon 7 dan 8. Gen SMN1 tidak dapat dikesan
pada kebanyakan kes SMA disebabkan oleh kehilangan atau penukaran bes tersebut.
Kebiasaanya, kehilangan gen SMN1 dapat dikesan menggunakan kaedah Reaksi Rantai
Polimer-Enzim Pembatasan (PCR-RE). Kaedah ini memerlukan masa yang lama, kos
yang tinggi dan memerlukan pencernaan enzim pembatasan yang memerlukan banyak
jumlah DNA yang diamplifikasi dimana ia akan muncul selepas pencernaan dan
berkemungkinan menunjukkan keputusan yang salah. Untuk mengatasi masalah
tersebut, kaedah altenatif menggunakan primer alel-spesifik khusus untuk diagnosis
molekul SMA lebih menjimatkan masa dan kos. Platform ‘freeze-dry’ telah digunakan
pada multiplex Reaksi Rantai Polimer-Alel Spesifik (AS-PCR) untuk pembangunan kit
yang stabil suhu. Sejumlah satu ratus empat puluh tiga (143) sampel daripada pesakit
yang disyaki menghidapi SMA telah digunakan di dalam kajian ini. Kaedah diagnosis
molekul menggunakan PCR-RE telah dilakukan untuk mengesan kehilangan dan
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kehadiran gen SMN1 didalam semua sampel tersebut. Lima puluh enam sampel telah
dikesan mempunyai kehilangan gen SMN1, sementara 87 sampel lagi telah dikesan tidak
mengalami kehilangan gen tersebut. DNA telah diekstrak menggunakan kit komersil
yang sedia ada. Untuk menilai keberkesanan kaedah AS-PCR, kesemua 143 sampel
telah dianalisa semula menggunakan kaedah AS-PCR. Untuk mengesan amplifikasi
PCR dan mengelakkan keputusan yang salah, gene ‘housekeeping’ (β-globin gene) telah
digunakan sebagai kontrol dalaman. Keputusan daripada kedua-dua kaedah
kemudiannya telah di bandingkan dan dinilaikan dari segi masa kajian dan kos setiap
sampel. Kemudian, analisis kesensitiviti, ketepatan dan kestabilan untuk kit stabil suhu
AS-PCR telah diperhatikan dan dinilai. Seterusnya, kit stabil suhu AS-PCR telah
dianalisis keatas sampel SMA Jepun. Kajian ini telah menunjukkan 100% keputusan
yang sama diantara kaedah PCR-RE dan AS-PCR. Sementara, kit stabil suhu AS-PCR
juga menunjukkan 100% ketepatan dan kesensitifan diantara kaedah PCR-RE dan AS-
PCR biasa. Berdasarkan ujian kestabilan kit stabil suhu AS-PCR menunjukkan
sekurang-kurangnya 2.5 tahun kestabilan pada suhu dibawah 4°C. Keputusan kajian
menunjukkan kit stabil suhu AS-PCR adalah berkesan standing teknik PCR-RE untuk
pengesanan kehilangan gen SMN1. Seterusnya, penilaian diagnostik keatas populasi
Jepun menunjukkan ketepatan kit ini adalah 98% sementara kesensitifannya tetap pada
100%. Kesimpulannya, pengecualian pencernaan enzim telah menjadikan kaedah AS-
PCR lebih murah dan pantas berbanding kaedah lama. Ia dapat mengurangkan lima kali
ganda masa dan menjimatkan 69% kos setiap sampel. Kit stabil suhu AS-PCR juga
menunjukkan keberkesanan dan juga kelebihannya berbanding kaedah PCR-RE didalam
diagnosis molekul SMA yang mana menunjukkan ia boleh digunapakai di dalam
diagnosis rutin SMA.
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DEVELOPMENT OF EZDNA DIAGNOSTIC KIT FOR THE DETECTION OF
HOMOZYGOUS DELETION OF SMN1 GENE IN SPINAL MUSCULAR
ATROPHY (SMA) PATIENTS
ABSTRACT
Spinal Muscular Atrophy (SMA) is the second most frequent fatal autosomal recessive
disorder of childhood. The incidence of this disease is approximately 1 in 10000 live
births. SMA is characterized by progressive muscle weakness resulting from
degeneration and loss of motor neurons in the anterior horn of spinal cord. The
responsible genes for SMA are Survival of Motor Neuron (SMN). SMN1 and SMN2
genes share over 99.8% sequence homology and they can be distinguished by base
changes in both exons 7 and 8. SMN1 gene is not detectable in majority of SMA cases
due to either deletion or conversion. Conventionally, the homozygous deletion of SMN1
gene is detected using Polymerase Chain Reaction-Restriction Enzyme (PCR-RE)
method. This method is time consuming, expensive and requires restriction enzyme
digestion and a considerably high amount of amplified DNA to be visible after
digestion. This may lead to false-negative results. To avoid these problems, we have
developed an alternative method using an allele-specific primer for the molecular
diagnosis of SMA which is more time-saving and cost-effective. The freeze dry platform
was applied to the multiplex AS-PCR for the development of a thermostabilize
diagnostic kit. A total of one hundred and forty three samples of clinically suspected
SMA were included in this study. Conventional molecular diagnosis using PCR-RE was
done to detect the presence or absent of SMN1 deletion in these samples. Fifty-six
samples were found to have deletion of the SMN1, while the remaining 87 samples were
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found to have no deletion of the gene. To evaluate the reliability of the AS-PCR method,
all 143 samples were then re-analyzed using AS-PCR. To monitor the PCR
amplification and to avoid the false negative results, a housekeeping gene (β-globin
gene) was used as an internal control. The results from both methods were subsequently
compared and evaluated for the experimental duration and per sample cost. The
sensitivity, specificity and stability of the thermostabilized AS-PCR were monitored and
subsequently analyzed. This thermostabilized AS-PCR was then tested on Japanese
SMA samples. Our study showed 100% similarity between those using PCR-RE and
AS-PCR. The thermostabilized AS-PCR also showed 100% specificity and sensitivity
with PCR-RE and AS-PCR methods. Based on the accelerated stability, the
thermostabilized AS-PCR has the minimum of 2.5 years shelf life in temperature below
4°C. Our results suggest that the thermostabilized AS-PCR is a reliable technique when
compared to the PCR-RE method in the screening of SMN1 deletion.  Furthermore, the
diagnostic evaluation on Japanese population suggested that the specificity of the kit is
98% while the sensitivity remains 100%. In conclusion, the exclusion of digestion step
makes AS-PCR method cheaper and faster compared to the conventional method. It can
reduce almost five times of the time and 69% of the cost per sample. The
thermostabilize AS-PCR also reliable and superior over PCR-RE method in the
molecular diagnosis of SMA, suggesting that it could be applied in the routine diagnosis
of SMA.
CHAPTER 1
INTRODUCTION
1.1 The Overview of Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is the autosomal recessive genetic disease which can
lead to infant mortality (Robert et. al., 1970; Pearn 1973, 1978; Czeizel and Hamula,
1989). It is the second most common lethal genetic disease leading to childhood death
after cystic fibrosis (Steward et. al., 1998). The incidence of this disease is 1 in 10,000
live births while 1 in 40 normal people carry one copy of this lethal gene (Adreassi et.
al., 2001). Markowitz et al. (2004) was reported, the early founder of SMA was
described by Guido Werdnig and Johann Hoffmann. The main cause for SMA is the
degeneration of alpha-motor neurons that leads to the progressive muscle weakness.
This alpha-motor neuron was located at the anterior horn of the spinal cord. The
degeneration of this neuron could lead to the failure of transmission of the impulse from
brain to the muscle neuron. When the impulse did not normally function, the normal
function of the muscle will reduce and muscle will slowly shrink and atrophy.
Furthermore, most of the SMA patients commonly show the general symptoms such as
2muscle atrophy, weakness of cry, poor muscle tone, scoliosis, hypotonia and feeding
difficulties (Zerrez et al., 1995). The proximal muscles of SMA patients are mainly
weaker than the distal muscle due to the location which was closest to the spinal cord.
1.1.1 Classification of SMA
Spinal Muscular Atrophy is classified based on age of onset and the clinical severity, as
described in the International SMA Consortium Meeting (26th to 28th June 1992) in
Bonn, Germany (Munsat et al., 1992) (Table 1.1). This guideline was very useful for the
determination of the prognosis and management of SMA. However, the clinical
symptoms of SMA commonly overlap with other neuromuscular disorders (Chien et al.,
2005). Hence, many affected patients died due to the misdiagnosis of the clinical
symptoms and lack of awareness among the clinician. In some condition, the molecular
genetic analysis is useful for the confirmation of the clinical diagnosis (Chien et al.,
1995).
1.1.1(a) Type I SMA
Type I SMA is the severe type of SMA and it is also known as Werdnig-Hoffmann
disease or acute SMA. Patient with type I SMA is diagnosed by the early age of onset
which started between 0 to 6 months of age. Type I SMA patient usually have a very
limited life expectancy (less than 2 years). Most of the patients are not able to sit without
support. Generally, patients diagnosed with this form have very little control of their
heads and they also cough and cry weakly. They lose the ability to swallow and feed
3before they reach 1 year of age. Over time, their trunk and limbs will be weakened and it
normally spreads to the intercostals muscles, making an abnormal respiratory cycle. The
risk of early mortality is usually associated with bulbar dysfunction and respiratory
complications.
1.1.1(b) Type II SMA
An intermediate form of SMA is the type II SMA. Patient with type II SMA is generally
diagnosed around 6 to 18 months of age, but it may start earlier. Some of these patients
which have been classified to have SMA type II are able to sit up without support while
others can remain sitting if they are positioned, but they still cannot sit without any
support. In the other case, some of the patients could stand with support and this showed
that they have a better muscle development than others. However, this patient is still
unable to walk. In type II SMA patient, some of them will experience reducing weight
due to the bulbar weakness which combined with the swallowing difficulties.
Furthermore, these patients may have problems with coughing and with cleaning
secretions from the trachea, and as well as tongue fasciculation and later they can suffer
from scoliosis and contractures. Their life expectancy is around 10 to 40 years.
1.1.1(c) Type III SMA
Kugelberg-Welander syndrome is also known as type III SMA or juvenile SMA. The
actual age varies but according to the consortium, the age of onset for type III SMA is
after 18 months. Wirth et al. (2000) divided the type III SMA into two types, which is
4type III(a) SMA and type III (b) SMA. Type III(a) SMA is when the disease started
before 3 years of age, while if  the onset is later, it is called type III(b) SMA. The major
difference between both types is the preservation of the ability to walk. Patients with
type III(a) are able to walk until they are 20, while type III(b) patients are able to walk
for their whole life. The general problems in SMA type III patient are difficulties in
swallowing and coughing when feeding. Scoliosis will develop later in their life.
1.1.1(d) Type IV SMA
The adulthood form of SMA is also known as type IV SMA. There is no consensus on
the age of onset of type IV SMA. Several cases study have reported that this type of
SMA started after 10 years of age (Russman et al., 1995) while another report by Wang
et al. (2007) stated that their weakness normally emerges during the second or third
decade of life, or at about 30 years of age. Normally, the motor function involvement is
mild and there are no problems with deglutition or respiration. Type IV SMA patients
are able to walk normally and have normal life expectancy.
5Table 1.1 Classification of Spinal Muscular Atrophy based on the International
SMA Consortium Meeting (26th to 28th June 1992) in Bonn, Germany
(Munsat et al., 1992).
Phenotype Age of Onset Life Span Motor Milestone
SMA I Before six months Reduced Sit with support only
SMA II 6-18 months Adolescence Independent sitting
SMA III After 12 months Adult Independent ambulation
SMA IV Adulthood Normal Normal
6Figure 1.1 A Malay boy with Type II SMA (Adapted from Watihayati et al., 2007).
This patient passed away in February 2010.
7Figure 1.2 A Malay girl with Type III SMA (Adapted from Watihayati et al., 2007).
This patient is still undergoing treatment at Hospital USM.
81.2 SMA as an Autosomal Recessive Disease
Spinal Muscular Atrophy is one of the autosomal recessive diseases inheritance pattern,
leading to the early death in children. In autosomal recessive disease, two copies of the
gene must be mutated for a person to be affected. In most of the SMA cases, patient
usually has unaffected parents but they carry a single copy of the mutated gene while the
other gene is normal. They are called a carrier. When a carrier marries another carrier,
they will have a 25% chance with each pregnancy of having an affected child.
As an example in Figure 1.3, ‘A’ is the normal gene and ‘a’ is the mutated gene. When
both the parents have an ‘Aa’ gene which mean they are a carrier, they will have 25%
chance to get a normal homozygous ‘AA’ child, 50% chance a carrier ‘Aa’ heterozygous
child and 25% an affected child (aa) which carry both mutated genes from the parents
(Figure 1.3).
9Heterozygous
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Heterozygous
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Figure 1.3 This figure shows an autosomal recessive inheritance pattern in Spinal
Muscular Atrophy.
10
1.3 Diagnosis of SMA
In order to diagnose patients with SMA, the general symptoms of SMA need to be
clinically present. Since SMA is caused by the progressively degeneration of the alpha-
motor neuron, the affected neuron is only the motor neuron, not the sensory neuron.
SMA patients therefore commonly present with weakness and atrophy of the voluntary
muscle of the legs, arms and trunk. Most of the SMA cases could be identified with the
molecular genetic testing of SMN1 gene while in some cases, the clinical diagnosis are
essential for the confirmation of SMA due to the heterozygous deletion or other
mutations in the SMN1 gene (Hahnen et al., 1995; Rodrigues et al., 1995). In addition,
due to the low prevalence of SMA, the diagnosis of SMA becomes quite challenging.
There are numbers of neurogenetic diseases that could present with similar symptoms of
SMA. Hence, diagnosis of clinical presentation of SMA should be investigated with care
(Araújo et al., 2005) since these clinical signs can also be observed in other
neuropathologies (Baioni et al., 2010). Generally, SMA patients manifest clinical
characteristic signs such as hypotonia, tongue fasciculation and scoliosis.
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1.3.1 Clinical Features
1.3.1(a) Hypotonia
One of the clinical features of SMA is hypotonia. Hypotonia is a symptom where the
muscle state is very low, which is caused by the defect of the motor nerve control by the
brain. Most of the SMA cases which was detected in the infant state, the patient will
have ‘floppy infant syndrome’ which is described an abnormal limpness when an infant
is put in prone position. They easily slip through one’s hand as showed in figure 1.4. The
patient usually could not control the movement of their head and have difficulties in
feeding. Usually, this patient is classified in the type I SMA and died before 6 months of
age.
1.3.1(b) Scoliosis
Scoliosis is a condition which a person’s spine is curved from side to side. The spine
will form as an ‘S’ rather than a straight line (Figure 1.5). It is classified as either
congenital (vertebral anomalies present at birth), idiopathic (unknown cause) or
neuromuscular. The severe cases of scoliosis can lead to diminishing lung capacity,
which put pressure on the heart and restricting physical activities. Patient with scoliosis
is examined by physical examination involving the skin to indicate neurofibromatosis,
the feet for cavovarus deformity, abnormal reflexes and muscle tone spacity. Generally
there is no medical treatment for scoliosis because of its complexity. Patient who suffers
from scoliosis usually will have a physical therapy, using a brace to support the body
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and surgery to increase their self care activities and to prevent the scoliosis to become
worsen.
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Figure 1.4 The figure shows the SMA patient with hypotonia. (Adapted from
http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/17229.jp
g)
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Figure 1.5 This figures show SMA patient spine who suffered from scoliosis. Figure
A shows the actual patient spine (Adapted from
http://www.nlm.nih.gov/medlineplus/ency/imagepages/1114.htm) and
Figure B shows the cob angle for the measurement of levoscoliosis
(Adapted from http://en.wikipedia.org/wiki/File:Scoliosis_cobb.gif)
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1.3.1(c) Tongue Fasciculation
Tongue fasciculation is an abnormal pattern of non rhythmical, unorganized, contraction
of individual muscle fibres across the surface of the tongue. The involuntary contraction
of the muscle fibres are generally innervated by a motor unit. The fasciculation can often
be visualised and take the form of a muscle twitch or dumpling under the skin, but
usually do not generate sufficient force to move a limb. The tongue fasciculation may
represent a condition such as in SMA.
1.3.2 Muscle Biopsy
A muscle biopsy is a procedure to remove a piece of muscle tissue from the respective
target muscle. The procedure of muscle biopsy is involving a small surgical incision
using a biopsy needle (figure 1.6). A muscle biopsy is generally used in the
determination of a muscle and nerve problem such as nerve system, connective tissue,
vascular system or musculoskeletal system (Araújo et al., 2005; Wirth et al., 2006). In
SMA patient, a muscle biopsy can help the clinician to distinguish the myopathies
(pathology is in the muscle tissue) and neuropathies (pathology is at the nerves
innervating the muscle). In some cases, muscle biopsy is unnecessary but in other cases,
it can help to clarify the muscle type and get a clear picture of which type of muscle
dominates their body (Pons et al., 1996).
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Figure 1.6 The figure shows the procedure for muscle biopsy (Adapted from
http://www.hes.cahs.colostate.edu.html)
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1.3.3 Electromyography (EMG)
Electromyography (EMG) is a technique to evaluate and record the electrical activity
produced by the skeletal muscle. EMG is performed by an electromyograph and the
signal which is produced is called an electromyogram (figure 1.7). Electromyograph will
detect the electrical potential that is generated by muscle cells when these cells are
electrically or neurogically activated (Reed, 2002).
The muscle abnormalities, activation level, recruitment order and biomechanics of
human movement can be analyzed by EMG. Normal muscle tissue is electrically
inactive while in the resting condition while in the neurophatic disease, the action
potential amplitude and duration is twice the normal because of the increased number of
fibres per motor unit because of the innervations of denervated fibres (Araújo et al.,
2005; Wirth et al., 2006). In contrast, the myophatic disease shows the action potential
amplitude and duration is decreased than the normal level.
1.3.4 Nerve Conduction Study (NCS)
Nerve Conduction Study (NCS) is the procedure to evaluate the function and the ability
of electrical conduction of the normal and sensory nerve of the human body (figure 1.8).
In NCS test, the Nerve Conduction Velocity (NCV) measurement was made to set the
actual mean of the test but in certain cases, this measurement may be misleading because
it is the only one measurement in the test suite.
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The NCS consist of four components which are motor NCS, sensory NCS, F-wave study
and H-reflex study. All of these components were done to stimulate and record the wave
and reflex of the motor nerves and muscle potential. The interpretation of NCS is
complex, but generally the abnormality in motor nerves is indicated by the slowing of
the NCV wave (Araújo et al., 2005; Wirth et al., 2006). This test is not invasive, but can
be painful due to the electrical shock associated with the low electrical current.
19
Figure 1.7 The figure shows the example of the procedures for Electromyography
(EMG) (Adapted from http://cdn.nursingcrib.com/wp-
content/uploads/emg.jpg)
Figure 1.8 The figure shows the example of the procedures for Nerve Conduction
Study (NCS) (Adapted from http://www.drbezner.com/ncs.jpg)
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1.4 Molecular Analysis of SMA
1.4.1 Survival of motor neuron gene (SMN)
Almost sixteen years back, the inverted duplication of a 500kb element in a long arm of
a normal chromosome 5 (5q13) have been discovered by Lefebvre et al. (1995) which
contains the gene for type I SMA patient (figure 1.9). They found a 20kb gene which
encode 294 amino acid protein within the telomeric portion that known as survival of
motor neuron gene (SMN gene). This gene is also known as telomeric SMN gene
(SMNT) (Lefebvre et al., 1995). SMN gene is a component of a large highly stable
protein complex that can be found in both cytoplasmic and nuclear compartments (Liu
et. al., 1997; Lefebvre et. al., 1997; Meister et. al., 2000). The human SMN gene was
reported to have 8 exons (Lefebvre et al., 1995). However, Burglen et al. (1996) have
characterized the SMN gene and showed that it has 9 exons because exon 2 is devided
into two exons; exon 2a and 2b. The SMN gene stop codon was found in the exon 7
while the exon 8 is not translated.
The SMN protein is found throughout the body but in higher level in the spinal cord
(Coovert et al., 1997). The function of SMN protein in the spinal cord is in the
maintenance of the nerve cells that is called motor neurons. Healthy motor neurons are
critical because they will control the movement of the muscle. In cells, the SMN protein
is found in a sub nuclear form known as Gemini of Cajal bodies (Gems) because of its
similarities in number and size with Cajal bodies (CBs) (Liu and Dreyfuss, 1996). The
Gems also have the same response and metabolic condition as CBs. However, the
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presence of small nuclear ribonucleoprotein (snRNPs) in CBs has made it different from
Gems.  The snRNPs is a complex of snRNP which is consisted of U1, U2, U4/U6 and
U5 and it plays an important role in assembling the cellular machinery in the processing
molecules which is called pre-messenger RNA (pre-mRNA) (Liu and Dreyfuss, 1996).
The full length of SMN protein is needed for the interaction of this protein with other
protein to form a large complex of multiprotein.
The SMN protein, also has an additional function in nerve cells that is important for
dendrites and axons which are important for the transmission of impulses from nerve to
nerve and from nerves to muscles (Fan and Simard, 2002).
In the fetus period, the SMN gene is normally inactive and allows normal apoptosis in
the developing fetus (Soler-Botija et al., 2002). This gene becomes active in the healthy
mature fetus to stabilize the neuronal population. In its absence, programmed cell death
persists. The mechanism and timing of abnormal motor neuron death remain unknown
(Brzustowicz et al., 1990; Pern et al., 1978).
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Figure 1.9 This figure shows the location of the human chromosome 5 and the
location of the SMN gene in the chromosome. (Adapted from
http://www.ensembl.co.uk/)
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1.4.2 The SMN1 and SMN2 gene
A study by Coovert et al. (1997), found that the SMN protein is expressed from both
SMN1 and SMN2 genes. However, the exon 7 SMN1 gene is not detectable in 95% of
SMA cases due either deletion or conversion of the sequences (Lefebvre et. al., 1995).
The other 5% of non deleted SMA patients is believed to have intragenic mutations;
missense mutation, frameshift mutation, nonsense mutation, Alu-mediated deletion and
donor splice site mutation (Wirth et. al., 1999). The study by Coovert et al. (1997) also
demonstrated that the SMN2 gene was found in more than 95% of the controls at the
duplicated centromeric region of the chromosome 5 (Coovert et al., 1997), hence there is
no report about the patients who absent both of these genes.
Both of these genes share over 99.8% of the similar nucleotide and are different in only
five nucleotides. SMN1 and SMN2 can be distinguished by only 5 nucleotide differences
located in one in intron 6 (G>A), one in exon 7 (C>T), two in intron 7 (A>G; A>G) and
one in exon 8 (G>A)(Figure 1.10).
SMN1 and SMN2 expressed the same peptide sequence for the SMN gene. However,
because of one nucleotide difference in exon 7 (C>T) between SMN1 and SMN2 gene,
the alteration of one nucleotide in exon 7 SMN2 gene will cause the splicing of exon 7
during the transcriptional process, and later produce a truncated SMN2 protein (Lorson
et al., 1999). This truncated SMN2 gene is not stable in vivo and in vitro and it also could
not self-oligomerized (Hofmann et al., 2000).
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Rochette et al. (2001) reported that SMN2 is unique in man since the chimpanzee has
only multiple copy of SMN1 gene. The SMN1 gene is not present in most of SMA
patients; however they retain at least one copy of SMN2. (Figure 1.10)
However, in 10% of the cases, the SMN2 may also produce full lengh SMN protein
(Lefebvre et al., 1995). The severity of the disease depends on the efficiency of splicing
of this SMN2 in order to produce the full lengh SMN protein. The low level of SMN
could still allow the development of the embryo but the survival of motor neuron
sufficiency was still abnormal.
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Figure 1.10 This diagram shows (A) the inverted duplication of SMN1 and SMN2
gene and (B) the nucleotide differences between both genes.
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